‘Weeding the garden’ lets ALK+ lung cancer patients continue crizotinib

A study published in the International Journal of Radiation Oncology Biology and Physics shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease.

Science Codex